Copyright
©The Author(s) 2000.
World J Gastroenterol. Aug 15, 2000; 6(4): 565-568
Published online Aug 15, 2000. doi: 10.3748/wjg.v6.i4.565
Published online Aug 15, 2000. doi: 10.3748/wjg.v6.i4.565
Group | Case (n) | VEGF concentrations (ng/L) |
Normal control | 12 | 158.46 ± 41.84 |
Liver cirrhosis | 12 | 90.00 ± 22.42 |
Benign | 8 | 156.34 ± 41.34 |
HCC | 85 | 164.42 ± 76.07ab |
Small HCC | 34 | 154.46 ± 37.23 |
Large HCC | 51 | 173.52 ± 52.34c |
Without thrombi | 71 | 157.62 ± 53.42 |
Thrombi | 14 | 182.46 ± 35.61d |
p53 negative | 34 | 149.26 ± 41.29 |
p53 positive | 38 | 176.56 ± 53.29e |
PCNA negative | 36 | 165.26 ± 54.29 |
PCNA positive | 31 | 176.56 ± 53.29f |
- Citation: Niu Q, Tang ZY, Ma ZC, Qin LX, Zhang LH. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma. World J Gastroenterol 2000; 6(4): 565-568
- URL: https://www.wjgnet.com/1007-9327/full/v6/i4/565.htm
- DOI: https://dx.doi.org/10.3748/wjg.v6.i4.565